Literature DB >> 16097837

Real-world trials to answer real-world questions.

Nick Freemantle1, Lawrence Blonde, Bjorn Bolinder, Robert A Gerber, F D Richard Hobbs, Luc Martinez, Stuart Ross.   

Abstract

Currently, there is a discrepancy between clinical trials designed to assess the efficacy and safety of a new medication under investigation and the real-life questions that need to be addressed regarding the clinical use of the medication by patients, healthcare professionals and society. The data necessary to obtain regulatory approval may be of limited relevance to policy makers when calculating economic parameters such as value for money or cost effectiveness. 'Real-world' studies examine questions relevant to health policy and reimbursement. There are many different forms of clinical trials, but in designing trials incorporating realistic budget impact estimates the important issue is to ensure we are asking a sensible question and attempting to answer it with an appropriate experimental design. As an example, a real-world trial currently underway that examines scenarios of introducing inhaled insulin into clinical practice is described.

Entities:  

Mesh:

Year:  2005        PMID: 16097837     DOI: 10.2165/00019053-200523080-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  15 in total

1.  Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.

Authors:  Nick Freemantle; Lawrence Blonde; Didier Duhot; Marcus Hompesch; Robert Eggertsen; F D Richard Hobbs; Luc Martinez; Stuart Ross; Björn Bolinder; Elmar Stridde
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

2.  Should clinical trials with concurrent economic analyses be blinded?

Authors:  N Freemantle; M Drummond
Journal:  JAMA       Date:  1997-01-01       Impact factor: 56.272

3.  Time-action profile of inhaled insulin.

Authors:  L Heinemann; T Traut; T Heise
Journal:  Diabet Med       Date:  1997-01       Impact factor: 4.359

4.  Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Authors:  M J Langman; D M Jensen; D J Watson; S E Harper; P L Zhao; H Quan; J A Bolognese; T J Simon
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

5.  Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?

Authors:  N Freemantle
Journal:  Health Policy       Date:  1999-03       Impact factor: 2.980

6.  Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.

Authors:  Teresa Quattrin; André Bélanger; Nancy J V Bohannon; Sherwyn L Schwartz
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

7.  Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

Authors:  W T Cefalu; J S Skyler; I A Kourides; W H Landschulz; C C Balagtas; S Cheng; R A Gelfand
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

8.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

Authors:  Priscilla A Hollander; Lawrence Blonde; Richard Rowe; Adi E Mehta; Joseph L Milburn; Kenneth S Hershon; Jean-Louis Chiasson; Seymour R Levin
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

9.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors:  A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  7 in total

1.  NICE says no to inhaled insulin: what lessons should we learn?

Authors:  Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Peer reviewed publications in 2005.

Authors: 
Journal:  Ochsner J       Date:  2006

Review 3.  Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

Authors:  Michael Schlander
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

4.  Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design.

Authors:  Thomas Strack; Luc Martinez; Stefano Del Prato; Larry Blonde; Burkhard Göke; Vincent Woo; Ann Millward; Ramon Gomis; Bill Canovatchel; David Lawrence; Nick Freemantle
Journal:  Diabetes Metab Syndr Obes       Date:  2009-01-20       Impact factor: 3.168

5.  Clinical research and medical care: towards effective and complete integration.

Authors:  José A Sacristán
Journal:  BMC Med Res Methodol       Date:  2015-01-09       Impact factor: 4.615

6.  Requirements for benefit assessment in Germany and England - overview and comparison.

Authors:  Victor Ivandic
Journal:  Health Econ Rev       Date:  2014-08-28

7.  Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.

Authors:  Thilo Beck; Christian Haasen; Uwe Verthein; Stephan Walcher; Christoph Schuler; Markus Backmund; Christian Ruckes; Jens Reimer
Journal:  Addiction       Date:  2014-01-19       Impact factor: 6.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.